ArticleGut and liver2026
Global, Regional, and National Burden of Liver Cancer from 1990 to 2021 and Projections to 2050: A Global Burden of Disease Study 2021.
Article in Gut and liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: This study assessed the burden of liver cancer (LC) and its major risk factors from 1990 to 2021, with projections to 2050. Methods: The global and regional LC burden from 1990 to 2021 was extracted from the Global Burden of Disease Study 2021, and stratified by age, sex, Sociodemographic Index (SDI), region, and etiological category. Trends for the age-standardized mortality rate (ASMR) and age-standardized disability-adjusted life year rate (ASDR) were evaluated using estimated annual percentage changes. Attributable risk factors, including alcohol use, drug use, a high body mass index, tobacco use, and high fasting plasma glucose levels, were examined. Projections of the LC burden to 2050 were modeled under baseline and hypothetical risk elimination scenarios. Results: The global ASMR of LC remained stable, from 5.86 per 100,000 population (95% uncertainty interval [UI], 5.38 to 6.46) in 1990 to 5.65 (95% UI, 5.13 to 6.30) in 2021. Regions with an initially high ASMR showed increases until the early 2000s, then decreased. The LC burden increased sharply with age and was consistently higher in males, particularly in high-SDI regions. Mortality varied by etiology, with hepatitis B virus as the leading cause, followed by hepatitis C virus and alcohol use. Major risk factors were alcohol and tobacco use among males and drug and alcohol use among females. By 2050, the ASMR and ASDR of LC are projected to reach 6.23 per 100,000 population (95% UI, 4.94 to 8.09) and 158.91 (95% UI, 125.34 to 210.28), respectively, but could decrease to 5.32 (95% UI, 4.21 to 6.95) and 135.33 (95% UI, 106.74 to 179.05) under improved metabolic and behavioral risk scenarios. Conclusions: Despite public health interventions, LC is estimated to maintain a significant global burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.